Melfalán Tarbis (Melphalan)

Melphalan works by attaching alkyl groups to DNA bases, creating covalent cross‑links that prevent DNA strands from separating. This blocks replication and transcription, causing cell‑cycle arrest and ultimately leading to programmed cell death (apoptosis) in rapidly dividing cancer cells.

The exact dose of melphalan is individualized and set by the prescribing oncologist based on factors such as the specific cancer type, disease stage, patient weight or body surface area, renal function, and concurrent therapies. No standard dosing can be provided without a medical prescription.

Melphalan is classified as potentially harmful to the fetus and is generally contraindicated during pregnancy unless the therapeutic benefit justifies the risk. It is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment.

To request Melfalán Tarbis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to alkylating agents such as cyclophosphamide and chlorambucil, but it is often preferred for high‑dose regimens in multiple myeloma and certain solid tumours because of its potency and pharmacokinetic profile. Toxicity patterns are similar, with myelosuppression being the dose‑limiting factor.

Melfalán Tarbis should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and follow aseptic techniques when preparing for intra‑arterial or intravenous administration.

The product is supplied as a sterile injectable solution for intra‑arterial or intravenous infusion. Administration is performed by qualified healthcare professionals in a clinical setting, following institutional protocols for infusion rate, pre‑medication, and monitoring of vital signs and laboratory parameters.

Serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies such as therapy‑related leukemia, pulmonary fibrosis, renal toxicity, and rare cardiac complications. Patients should be closely monitored with regular blood counts, renal and pulmonary function tests, and clinical assessment for infection signs.

Melphalan is contraindicated in patients with known hypersensitivity to the drug, severe uncontrolled infections, significant bone‑marrow failure, or those who are pregnant unless the benefit outweighs the risk. Caution is also advised for individuals with impaired renal or hepatic function and for patients receiving other myelosuppressive therapies.